ADAMTS-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-2 (UniProt O95450), expressed in HEK293 cells. Procollagen I/II N-proteinase used in collagen processing assays, inhibitor IC50 studies, and antibody validation experiments.
Expression system
HEK293
Cat. #
REC-ADAMTS2

In stock

SKU
REC-ADAMTS2
$498.00

Target Overview

ADAMTS-2 (A Disintegrin And Metalloproteinase with Thrombospondin Motifs 2; UniProt O95450) is a secreted zinc-dependent metalloproteinase of the ADAMTS family, encoded by the ADAMTS2 gene on human chromosome 5q35. The full-length protein comprises 1,211 amino acids and is processed in the secretory pathway before deposition into the extracellular matrix. Its principal catalytic activity (EC 3.4.24.14) is the cleavage of N-terminal propeptides from procollagens I and II, a prerequisite step for fibril assembly in connective tissue. It does not process type III procollagen. Beyond its classical procollagen substrate, ADAMTS-2 cleaves lysyl oxidase (LOX) at a site downstream of the LOX propeptide cleavage site, generating a short LOX form with reduced collagen-binding activity (PubMed: 31152061). This recombinant is produced by transient expression in HEK293 cells, a mammalian system that supports the glycosylation and secretory processing characteristic of the native enzyme. Researchers select HEK293-expressed ADAMTS-2 over bacterially produced forms specifically because correct folding of the prodomain, catalytic, disintegrin-like, and thrombospondin modules is required for enzymatic activity and for generating a conformationally relevant antigen. In the laboratory, this recombinant is used in fluorogenic or HPLC-based procollagen propeptide cleavage assays, in dose-response inhibitor screens measuring IC50 against candidate small molecules, and as a positive-control antigen in Western blot and IHC antibody validation experiments. Researchers performing antibody validation can pair this recombinant directly with the matched Triple Point Biologics anti-ADAMTS-2 antibody (catalog RP-ADAMTS2), which has been validated for Western blot against human ADAMTS-2 with predicted cross-reactivity to monkey and dog orthologues.

Background

ADAMTS-2 is the founding procollagen N-proteinase of the ADAMTS superfamily, a group of secreted, multi-domain metalloproteinases that act on extracellular matrix components. Its role in removing the N-terminal propeptide from procollagens I and II makes it a rate-limiting participant in fibrillar collagen maturation: propeptide retention prevents collagen monomers from assembling into normal fibrils, resulting in the structurally disordered collagen characteristic of Ehlers-Danlos syndrome type VIIC (dermatosparaxis) in humans and equivalent conditions in cattle and cats. These loss-of-function phenotypes have made ADAMTS-2 a classical model for studying the relationship between propeptide processing and collagen fibril diameter regulation in connective tissue research. More recent work has placed ADAMTS-2 in a broader biological context. Apte SS (2026) provides a comprehensive overview of ADAMTS protease biology, situating ADAMTS-2 within the structural and functional framework of the family, including domain architecture relevant to substrate recognition and inhibitor design. Beyond structural connective tissue, ADAMTS-2 expression has been characterised in vascular biology: Altuntaş C et al. (2026) demonstrated that hypoxia reprograms VEGF signaling to differentially control ADAMTS2 and ADAMTS3 expression in endothelial cells, suggesting a role in the vascular remodelling response to low-oxygen conditions. ADAMTS-2 has also been investigated as a research target in oncology. Ning J et al. (2026) reported that ADAMTS-2 drives prostate cancer progression through activation of FAK/PI3K/AKT signaling and suppression of ferroptosis via COL1A1, identifying a mechanistic link between extracellular matrix remodelling and tumour cell survival pathways. In a separate disease context, Gao S et al. (2026) studied ADAMTS-2 in a lipopolysaccharide-induced acute respiratory distress syndrome model, finding that it modulates inflammation, autophagy, and barrier integrity through PI3K/AKT/mTOR signaling — characterising ADAMTS-2 as a participant in inflammatory extracellular matrix remodelling beyond its canonical connective tissue function. Together, this body of published work illustrates why researchers require a well-folded, enzymatically active recombinant ADAMTS-2 for mechanistic studies, substrate identification, and inhibitor development across fibrotic, oncological, and inflammatory research programmes. The HEK293-expressed recombinant described here provides a biochemically relevant tool for these in vitro and ex vivo applications.

Applications

  • Procollagen I/II N-propeptide cleavage activity assay (HPLC or fluorogenic substrate format)
  • Inhibitor IC50 determination against candidate small-molecule or peptide ADAMTS-2 inhibitors
  • Antibody validation positive control for Western blot (pair with matched antibody RP-ADAMTS2)
  • Substrate specificity profiling and identification by mass spectrometry-based degradomics
  • Lysyl oxidase (LOX) cleavage assay to characterise downstream LOX activity modulation
  • Kinetic parameter (Km, kcat) determination for procollagen peptide substrates
  • Dose-response ECM remodelling studies in cell-free or ex vivo matrix systems

References

  1. Apte SS. An Overview of ADAMTS Proteases. Methods Mol Biol. 2026. doi: 10.1007/978-1-0716-5218-3_1. PMID: 41917349.
  2. Altuntaş C et al. Hypoxia reprograms VEGF signaling to differentially control ADAMTS2 and ADAMTS3 expression in endothelial cells. Tissue Cell. 2026. doi: 10.1016/j.tice.2026.103636. PMID: 42224870.
  3. Ning J et al. ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1. Front Oncol. 2026. doi: 10.3389/fonc.2026.1784882. PMID: 42125710.
  4. Gao S et al. ADAMTS2 Modulates Inflammation, Autophagy, and Barrier Integrity Through PI3K/AKT/mTOR Signaling in LPS-Induced Acute Respiratory Distress Syndrome. Immun Inflamm Dis. 2026. doi: 10.1002/iid3.70429. PMID: 42011035.
  5. McDonald MF et al. Seizure-presenting IDH-wildtype glioblastoma and the upregulation of a synaptic signature. J Neurosurg. 2026. doi: 10.3171/2025.11.JNS251412. PMID: 41962162.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant ADAMTS-2 on SDS-PAGE or Western blot?

The full-length ADAMTS-2 protein (UniProt O95450) encodes 1,211 amino acids with a predicted unprocessed MW of ~134 kDa. Under reducing SDS-PAGE conditions, this recombinant — expressed in HEK293 cells — typically resolves between 150–175 kDa due to N-linked glycosylation added by the mammalian secretory pathway. The exact apparent MW can shift slightly depending on gel percentage; a 6–8% gel is recommended. Under non-reducing conditions, expect a modest upward shift. This glycoform pattern mirrors the native secreted enzyme, which is relevant when using this protein as a positive control alongside antibody RP-ADAMTS2.

What processing form of ADAMTS-2 is present in this recombinant — full-length, propeptide-removed, or mature form?

This recombinant is expressed as the secreted, processed form of ADAMTS-2 from HEK293 cells. The signal peptide (residues 1–29) is removed co-translationally, and the furin-susceptible propeptide is cleaved in the secretory pathway, yielding the mature, catalytically active metalloproteinase domain-containing form. It is not the full 1,211-residue precursor. The mature form retains the ADAMTS ancillary domains — disintegrin-like, thrombospondin type-1, cysteine-rich, and spacer — that are required for substrate recognition and ECM localization. This is the enzymatically relevant species for procollagen N-propeptidase assays.

What substrates does recombinant ADAMTS-2 cleave and how do I set up a procollagen N-propeptidase activity assay?

ADAMTS-2 (EC 3.4.24.14) cleaves the N-terminal propeptides of procollagens I and II but not type III procollagen. For in vitro activity assays, recombinant type I or type II procollagen N-propeptide substrates are used; cleavage is monitored by SDS-PAGE band shift or by fluorogenic peptide substrates spanning the scissile bond. A standard starting point is 10–50 nM recombinant ADAMTS-2 with substrate in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 at 37°C. ADAMTS-2 also cleaves lysyl oxidase (LOX) downstream of the LOX propeptide site (PMID 31152061), which is relevant for LOX-biology experimental designs.

What buffer should I use for ADAMTS-2 recombinant activity assays and are there any inhibitors to avoid?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — is compatible with direct use in activity assays after dilution. Calcium (≥1 mM free Ca²⁺) is required for catalytic activity; chelators such as EDTA or EGTA will inhibit the enzyme and must be excluded from assay buffers. Likewise, avoid broad-spectrum metalloproteinase inhibitors (e.g., GM6001, 1,10-phenanthroline) unless they are your experimental variable. Zinc supplementation (1–5 µM ZnCl2) can stabilize activity during extended assay incubations. BSA (0.01–0.1%) may be added to dilution buffers to reduce adsorptive loss at low enzyme concentrations.

What starting concentration of recombinant ADAMTS-2 should I use in a dose-response or inhibitor IC50 experiment?

For inhibitor IC50 determinations, a working enzyme concentration of 5–20 nM is a practical starting range — low enough to avoid substrate depletion artifacts yet high enough for reliable signal above background. Confirm the linear range of your activity signal empirically with a titration (0.5–100 nM) before committing to IC50 runs. At concentrations above ~50 nM, substrate depletion can compress the apparent IC50. The 5 mM CaCl2 in the supplied buffer maintains metalloproteinase stability; dilute into assay buffer immediately before use and keep on ice to minimize activity loss prior to the reaction start.

Can I use this recombinant ADAMTS-2 protein as a positive control for Western blot with the matched RP-ADAMTS2 antibody?

Yes — this is a primary use case. REC-ADAMTS2 and RP-ADAMTS2 are produced from the same target sequence in the same lab, making them a guaranteed compatible pair for Western blot positive controls and antibody validation. Load 25–100 ng of REC-ADAMTS2 per lane (a 50 ng load is a reliable starting point on a standard 6–8% gel under reducing conditions). The RP-ADAMTS2 rabbit polyclonal detects a band in the 150–175 kDa region consistent with the glycosylated mature form. This pairing is also appropriate for establishing that your sample prep and transfer conditions are working before committing precious tissue lysates.

How much recombinant ADAMTS-2 should I load for a Western blot positive control lane?

A load of 50 ng per lane is a practical starting point when using the matched RP-ADAMTS2 antibody (SKU: RP-ADAMTS2). If signal is weak at primary antibody dilutions above 1:2000, increase the load to 100 ng. For antibody titration experiments (e.g., determining optimal primary antibody dilution), a two-fold serial dilution series from 200 ng down to 12.5 ng across lanes gives a clean signal-response curve. Run alongside a molecular weight ladder in the 100–250 kDa range. Avoid loading >200 ng if you are running this adjacent to cell lysate lanes, as high recombinant loads can cause band smearing.

How should I store and handle recombinant ADAMTS-2 to preserve enzymatic activity after receipt?

Upon receipt, confirm the protein arrived on dry ice, then transfer immediately to –20°C for long-term storage. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol) is formulated to maintain stability at –20°C. Aliquots are single-use; repeated freeze-thaw cycles progressively denature metalloproteinases and will reduce activity. For working dilutions, dilute into assay-compatible buffer on ice immediately before use. If aliquots will be used within one week, storage at 4°C is acceptable but not recommended beyond 7 days. Do not dilute to below ~0.1 µg/mL without carrier protein (BSA) to prevent surface adsorption loss.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →